Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Biohaven receives orphan status for MSA drug

Biohaven Pharmaceutical Holding Company has received orphan drug designation from the FDA for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase inhibitor, for the treatment of...

| By Kelley Gipson

Yale team ‘reengineers’ immune cells

Yale researchers have developed a new way to efficiently engineer immune cells, an advance which enhances the ability to fend off cancer and other diseases....